Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy

This potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapy

COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase 1/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida.

Evaxion and Pantherna announced that the tumor neoantigens, identified by Evaxion's PIONEER, demonstrates strong immune response

Evaxion today announced that the U.S. Food and Drug Administration (“FDA”) determined that the Company may proceed with its Phase 2b clinical trial of EVX-01.

Evaxion today announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies (cancer vaccines) EVX-01 and EVX-02 in the second quarter of 2023.

Evaxion has signed a Vaccine Discovery Collaboration Agreement with ExpreS²ion Biotech for the joint development of a novel cytomegalovirus (CMV) vaccine candidate

Evaxion announced today promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02.

Evaxion announced today its third quarter 2022 financial results and provided an operational and business update

Evaxion today announced that it intends to further increase its focus on its lead oncology assets EVX-01 and EVX-02/03 to bring them to clinical proof of concept followed by out-licensing. The Company further plans preclinical partnering of its early-stage programs under its infectious disease platforms.